Who are Dupilumab - Dose Reduction's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dupilumab (SAR231893), Dupilumab step-down, Dupilumab Injectable Product, Depemokimab (GSK3511294), Placebo matching depemokimab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dupilumab-dose-reduction.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Dupilumab - Dose Reduction — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dupilumab - Dose Reduction (Dupilumab - Dose Reduction) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-4 receptor antagonist monoclonal antibody. Area: Immunology.

marketed IL-4 receptor antagonist monoclonal antibody IL-4 receptor alpha (IL-4Rα) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Dupilumab - Dose Reduction (Dupilumab - Dose Reduction) — Johns Hopkins University. Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling to reduce type 2 inflammatory responses.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dupilumab - Dose Reduction TARGET	Dupilumab - Dose Reduction	Johns Hopkins University	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab (SAR231893)	Dupilumab (SAR231893)	Sanofi	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab step-down	Dupilumab step-down	Nantes University Hospital	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Dupilumab Injectable Product	Dupilumab Injectable Product	University of Virginia	marketed	IL-4 receptor antagonist monoclonal antibody	IL-4 receptor alpha (IL-4Rα)
Depemokimab (GSK3511294)	Depemokimab (GSK3511294)	GlaxoSmithKline	phase 3	IL-4 receptor antagonist monoclonal antibody	IL-4Rα (Interleukin-4 receptor alpha)
Placebo matching depemokimab	Placebo matching depemokimab	GlaxoSmithKline	phase 3	IL-4 receptor antagonist monoclonal antibody	IL-4Rα (Interleukin-4 receptor alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-4 receptor antagonist monoclonal antibody class)

GlaxoSmithKline · 2 drugs in this class
Johns Hopkins University · 1 drug in this class
Nantes University Hospital · 1 drug in this class
Sanofi · 1 drug in this class
University of Virginia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dupilumab - Dose Reduction — Competitive Intelligence Brief. https://druglandscape.com/ci/dupilumab-dose-reduction. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab